Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockadeFei Ju, Yong Luo, Chaolong Lin, Xian Jia, Zilong Xu, Rui Tian, Yanhua Lin, Min Zhao, Yating Chang, Xiaoxuan Huang, Shaopeng Li, Wenfeng Ren, Yaning Qin, Mengqin Yu, Jizong JiaSee the full list of authors
10 June 2022
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapyXiaoyi Jiang, Jian Wang, Xichen Zheng, Zhida Liu, Xinyu Zhang, Yuwei Li, Jonathan Wilhelm, Jun Cao, Gang Huang, Jinlan Zhang, Baran Sumer, Jayanthi Lea, Zhigang Lu, Jinming Gao, Min Luo
27 May 2022
Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumorsYinghan Su, Jiang Li, Weidan Ji, Gang Wang, Lin Fang, Qin Zhang, Lin Ang, Min Zhao, Yuan Sen, Lei Chen, Junnian Zheng, Changqing Su, Lunxiu Qin
24 May 2022
Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastomaTaylor J Aiken, Amy K Erbe, Lauren Zebertavage, David Komjathy, Arika S Feils, Matthew Rodriguez, Ashley Stuckwisch, Stephen D Gillies, Zachary S Morris, Jen Birstler, Alexander L Rakhmilevich, Paul M Sondel
20 May 2022
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapyMiriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y Bartee, Eric Bartee
16 May 2022
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib studyChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao YanSee the full list of authors
5 April 2022
Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpressionBin-Jin Hwang, Li-Chung Tsao, Chaitanya R Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, Xiao-Yi Yang, Gangjun Lei, Takuya Osada, Herbert Kim Lyerly, Michael A Morse, Zachary Conrad Hartman
31 March 2022
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumorsRocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, Rafael Álvarez, Teresa Macarulla, Maria C Riesco-Martinez, Helena Verdaguer, Carmen Guillén-Ponce, Martí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia del PozoSee the full list of authors
25 March 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanomaGalabina Bozhanova, Jehanne Hassan, Lizzie Appleton, Victoria Jennings, Shane Foo, Martin McLaughlin, Charleen ML Chan Wah Hak, Emmanuel C Patin, Eva Crespo-Rodriguez, Gabby Baker, Edward Armstrong, Matthew Chiu, Hardev Pandha, Adel Samson, Victoria RoulstoneSee the full list of authors
25 March 2022
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancerJacob P van Vloten, Kathy Matuszewska, Mark A A Minow, Jessica A Minott, Lisa A Santry, Madison Pereira, Ashley A Stegelmeier, Thomas M McAusland, Elaine M Klafuric, Khalil Karimi, Joseph Colasanti, D Grant McFadden, James J Petrik, Byram W Bridle, Sarah K Wootton
16 March 2022